Premium
Standard and new treatments in cutaneous B‐cell lymphomas
Author(s) -
Dreno Brigitte
Publication year - 2006
Publication title -
journal of cutaneous pathology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 75
eISSN - 1600-0560
pISSN - 0303-6987
DOI - 10.1111/j.0303-6987.2006.00544.x
Subject(s) - medicine , rituximab , lymphoma , radiation therapy , pathology , cutaneous lymphoma , dermatology , mycosis fungoides , surgery
Background: Primary cutaneous B‐cell lymphomas (PCBCL) are cutaneous non‐Hodgkin lymphomas and can be classified clinically and by prognosis. The aim of this paper is to perform a review of standard and new treatments. Method: This paper provides a literature review of the different treatments of PCBCL. Results: Surgery and radiotherapy remain the standard therapies in isolated cutaneous lesions. Systemic or intralesional interferon (IFN)‐α may be an alternative in PCBCL with diffuse cutaneous lesions. In aggressive forms with poor prognosis, polychemotherapy is the first line of treatment although rituximab and radioimmunotherapy are evolving therapeutic options. Conclusion: In the majority of cases, the treatment of CBCL is straightforward. In aggressive forms, new therapies and biologic therapies may be of real interest.